Publications
5538 Results
- Journal / Conference
- Journal of Clinical Oncology 17(8):2300-2308
- Year
- 1999
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9216 (INT-0131) (NCIC-CTG-BR.8)
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical trials group and the Southwest Oncology Group.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:9a(#27)
- Year
- 1999
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-9501
SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:333a(#1280)
- Year
- 1999
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9457
Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:331a(#1275)
- Year
- 1999
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9338
Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-a for advanced renal cell carcinoma. A Southwest Oncology Group study.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:468a(#1807)
- Year
- 1999
- Research Committee(s)
- Lung
- Study Number(s)
- S9705
Preliminary toxicity results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung cancer (SCLC).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:461a(#1777)
- Year
- 1999
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9509
A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:537a(#2072)
- Year
- 1999
- Research Committee(s)
- Melanoma
- Study Number(s)
- SWOG-9111 (EST-1690)
Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high-and low- dose IFNa2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:538a(#2079)
- Year
- 1999
- Research Committee(s)
- Melanoma
- Study Number(s)
- SWOG-9325 (EST-2690)
E2690: Intergroup immunological evaluation of IFNa2b dose-response in patients (Pts) with high-risk melanoma.
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:67a(#249)
- Year
- 1999
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8851 (INT-0101) (EST-5188)
Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101).
- Journal / Conference
- Proc of the American Society of Clinical Oncology 18:382a(#1475)
- Year
- 1999
- Research Committee(s)
- Gynecologic
- Study Number(s)
- SWOG-9521